|
|
|
|
| As additional mRNA therapeutics makers progress toward and into the clinic, we're gathering more knowledge about what makes our mRNA products "tick," and how our processes impact the overall quality of our products. Join this expert panel for a timely discussion in the mRNA therapeutics space. Registration is free thanks to the support of Millipore Sigma. |
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | The following article will outline the current state of COGS in the mRNA industry. But heaven forbid this be your normal conference panel write-up. No, below I share one expert’s insights in the form of a never-before released episode of The Price is Right…or perhaps more fittingly: The Price is…Sort Of, Almost, Not Quite Right! | |
|
|
|
By Carl Schoellhammer, DeciBio Consulting | Oligonucleotide therapeutics are experiencing a new wave of momentum. As the science evolves and the market opportunity expands, the landscape is poised for continued growth and diversification. | |
|
|
|
|
| Essential Strategies For IVT Optimization | Article | Roche CustomBiotech | Optimizing in vitro transcription (IVT) for mRNA is crucial to improving the stability of these molecules and enabling their large-scale production. |
|
|
|
|
|
|
|
| Improving Toxicology Testing For Inhalation Products | Article | Battelle | By embracing new approach methods, regulatory agencies can revolutionize toxicology testing. These methods can be adapted for various medications, including inhalers and nasal-administered drugs. |
|
|
| De-Risk mRNA Regulatory Approvals | Infographic | MilliporeSigma | Gain insight into how you can de-risk mRNA regulatory approvals with critical quality attribute characterization and lot release testing. |
|
|
|
|
| Biologics US 2025: Bringing Biopharma Breakthroughs to life | Join us, as Biologics US 2025 gathers North America’s biopharma leaders to tackle challenges in antibody and ADC R&D. See how experts are using AI-assisted design, novel protein targets, and advanced conjugation strategies to drive effective therapeutics. Don’t miss keynotes from Steve Turner and Ray Deshaies, GLIMPSE-1 human-first antibody insights from Wyatt McDonnell, and our Innovations & Breakthroughs Under the Stars Garden Party. Claim your free ticket. |
|
|
|
|
|
|
|
|
.png){kind=logo}
